Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 7, Issue 1, 2005, Pages 45-61

  De La Monte, Suzanne M ^a   Wands, Jack R ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Animal models; Diabetes mellitus; Insulin like growth factor; Insulin resistance; Review; Signal transduction

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; INSULIN; INSULIN RECEPTOR; SOMATOMEDIN; STREPTOZOCIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN MICROCIRCULATION; COGNITIVE DEFECT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOREACTIVITY; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC DISORDER; MULTIINFARCT DEMENTIA; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; TISSUE SPECIFICITY;

EID: 15244350991     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2005-7106     Document Type: Review

References (165)

1. P. Ye, Y. Xing, Z. Dai and A.J. D'Ercole, In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors, Brain Res Dev Brain Res 95 (1996), 44-54.
2. A.J. D'Ercole, P. Ye and J.R. O'Kusky, Mutant mouse models of insulin-like growth factor actions in the central nervous system, Neuropeptides 36 (2002), 209-220.
3. G.J. Popken, R.D. Hodge, P. Ye, J. Zhang, W. Ng, J.R. O'Kusky and A.J. D'Ercole, In vivo effects of insulin-like growth factor-I (IGF-I) on prenatal and early postnatal development of the central nervous system, Eur J Neurosci 19 (2004), 2056-2068.
4. A.J. D'Ercole, P. Ye, A.S. Calikoglu and G. Gutierrez-Ospina, The role of the insulin-like growth factors in the central nervous system, Mol Neurobiol 13 (1996), 227-255.
5. J.R. O'Kusky, P. Ye and A.J. D'Ercole, Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development, J Neurosci 20 (2000), 8435-8442.
6. A.J. D'Ercole, P. Ye and G. Gutierrez-Ospina, Use of transgenic mice for understanding the physiology of insulin-like growth factors, Horm Res 45(Suppl 1) (1996), 5-7.
7. M. Wozniak, B. Rydzewski, S.P. Baker and M.K. Raizada, The cellular and physiological actions of insulin in the central nervous system, Neurochem Int 22 (1993), 1-10.
8. L. Frolich, D. Blum-Degen, H.G. Bernstein, S. Engelsberger, J. Humrich, S. Laufer, D. Muschner, A. Thalheimer, A. Turk, S. Hoyer, R. Zochling, K.W. Boissl, K. Jellinger and P. Riederer, Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease, J Neural Transm 105 (1998), 423-438.
9. J.F. Poduslo, G.L. Curran, T.M. Wengenack, B. Malester and K. Duff, Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease, Neurobiol Dis 8 (2001), 555-567.
10. K. Gerozissis and G. Kyriaki, Brain insulin: regulation, mechanisms of action and functions, Cell Mol Neurobiol 23 (2003), 1-25.
11. A.J. D'Ercole, Expression of insulin-like growth factor-I in transgenic mice, Ann N Y Acad Sci 692 (1993), 149-160.
12. F. Folli, S. Ghidella, L. Bonfanti, C.R. Kahn and A. Merighi, The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system, Mol Neurobiol 13 (1996), 155-183.
13. P. Ye, Y. Umayahara, D. Ritter, T. Bunting, H. Auman, P. Rotwein and A.J. D'Ercole, Regulation of insulin-like growth factor I (IGF-I) gene expression in brain of transgenic mice expressing an IGF-I-luciferase fusion gene, Endocrinology 138 (1997), 5466-5475.
14. K.D. Dentremont, P. Ye, A.J. D'Ercole and J.R. O'Kusky, Increased insulin-like growth factor-I (IGF-I) expression during early postnatal development differentially increases neuron number and growth in medullary nuclei of the mouse, Brain Res Dev Brain Res 114 (1999), 135-141.
15. J.W. Unger, J.N. Livingston and A.M. Moss, Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects, Prog Neurobiol 36 (1991), 343-362.
16. J.W. Unger, A.M. Moss and J.N. Livingston, Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat, Neuroscience 42 (1991), 853-861.
17. A.R. Saltiel and J.E. Pessin, Insulin signaling pathways in time and space, Trends Cell Biol 12 (2002), 65-71.
18. B. Giovannone, M.L. Scaldaferri, M. Federici, O. Porzio, D. Lauro, A. Fusco, P. Sbraccia, P. Borboni, R. Lauro and G. Sesti, Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential, Diabetes Metab Res Rev 16 (2000), 434-441.
19. A. Ullrich, J.R. Bell, E.Y. Chen, R. Herrera, L.M. Petruzzelli, T.J. Dull, A. Gray, L. Coussens, Y.C. Liao and M. Tsubokawa, Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes, Nature 313 (1985), 756-761.
20. A.O. Shpakov and M.N. Pertseva, Structural and functional characterization of insulin receptor substrate proteins and the molecular mechanisms of their interaction with insulin superfamily tyrosine kinase receptors and effector proteins, Membr Cell Biol 13 (2000), 455-484.
21. M.G. Myers, X.J. Sun and M.F. White, The IRS-1 signaling system, Trends Biochem Sci 19 (1994), 289-293.
22. X.J. Sun, D.L. Crimmins, M.J. Myers, M. Miralpeix and M.F. White, Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1, Mol Cell Biol 13 (1993), 7418-7428.
23. D.G. Puro and E. Agardh, Insulin-mediated regulation of neuronal maturation, Science 225 (1984), 1170-1172.
24. J.F. Mill, M.V. Chao and D.N. Ishii, Insulin, insulin-like growth factor II, and nerve growth factor effects on tubulin mRNA levels and neurite formation, Proc Natl Acad Sci USA 82 (1985), 7126-7130.
25. K.A. Heidenreich and S.P. Toledo, Insulin receptors mediate growth effects in cultured fetal neurons. I. Rapid stimulation of protein synthesis, Endocrinology 125 (1989), 1451-1457.
26. K. Lam, C.L. Carpenter, N.B. Ruderman, J.C. Friel and K.L. Kelly, The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin, J Biol Chem 269 (1994), 20648-20652.
27. G. Kulik, A. Klippel and M.J. Weber, Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt, Mol Cell Biol 17 (1997), 1595-1606.
28. A.R. Alessi and C.P. Downes, The role of PI 3-kinase in insulin action, Biochim Biophys Acta 1436 (1998), 151-164.
29. M. Delcommenne, C. Tan, V. Gray, L. Rue, J. Woodgett and S. Dedhar, Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase, Proc Natl Acad Sci USA 95 (1998), 11211-11216.
30. B.M. Burgering and P.J. Coffer, Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction, Nature 376 (1995), 599-602.
31. H. Dudek, S.R. Datta, T.F. Franke, M.J. Birnbaum, R. Yao, G.M. Cooper, R.A. Segal, D.R. Kaplan and M.E. Greenberg, Regulation of neuronal survival by the serine-threonine protein kinase Akt, Science 275 (1997), 661-665.
32. M. Pap and G.M. Cooper, Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway, J Biol Chem 273 (1998), 19929-19932.
33. P.C. van Weeren, K.M. de Bruyn, A.M. de Vries-Smits, J. van Lint and B.M. Burgering, Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB, J Biol Chem 273 (1998), 13150-13156.
34. S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh and M.E. Greenberg, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, Cell 91 (1997), 231-241.
35. M. Hetman, J.E. Cavanaugh, D. Kimelman and Z. Xia, Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal, J Neurosci 20 (2000), 2567-2574.
36. E.M. Eves, W. Xiong, A. Bellacosa, S.G. Kennedy, P.N. Tsichlis, M.R. Rosner and N. Hay, Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line, Mol Cell Biol 18 (1998), 2143-2152.
37. F. Condorelli, P. Salomoni, S. Cotteret, V. Cesi, S.M. Srinivasula, E.S. Alnemri and B. Calabretta, Caspase cleavage enhances the apoptosis-inducing effects of BAD, Mol Cell Biol 21 (2001), 3025-3036.
38. A.P. Halestrap, E. Doran, J.P. Gillespie and A. O'Toole, Mitochondria and cell death, Biochem Soc Trans 28 (2000), 170-177.
39. T. Hirsch, S.A. Susin, I. Marzo, P. Marchetti, N. Zamzami and G. Kroemer, Mitochondrial permeability transition in apoptosis and necrosis, Cell Biol Toxicol 14 (1998), 141-145.
40. J. Nakae, Y. Kido and D. Accili, Distinct and overlapping functions of insulin and IGF-I receptors, Endocr Rev 22 (2001), 818-835.
41. M.J. Carson, R.R. Behringer, R.L. Brinster and F.A. Mc-Morris, Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice, Neuron 10 (1993), 729-740.
42. W. Ni, K. Rajkumar, J.I. Nagy and L.J. Murphy, Impaired brain development and reduced astrocyte response to injury in transgenic mice expressing IGF binding protein-1, Brain Res 769 (1997), 97-107.
43. S. Doublier, C. Duyckaerts, D. Seurin and M. Binoux, Impaired brain development and hydrocephalus in a line of transgenic mice with liver-specific expression of human insulin-like growth factor binding protein-1, Growth Horm IGF Res 10 (2000), 267-274.
44. J. Zhong, J. Deng, B. Ghetti and W.H. Lee, Inhibition of insulin-like growth factor I activity contributes to the premature apoptosis of cerebellar granule neuron in weaver mutant mice: in vitro analysis, J Neurosci Res 70 (2002), 36-45.
45. F. Mauvais-Jarvis, R.N. Kulkarni and C.R. Kahn, Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance, Clin Endocrinol (Oxf) 57 (2002), 1-9.
46. F. Mauvais-Jarvis and C.R. Kahn, Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what can we learn from transgenic and knockout mice? Diabetes Metab 26 (2000), 433-448.
47. R.N. Kulkarni and T. Okada, Tissue-specific targeting of the insulin receptor gene. Endocrine 19 (2002), 257-266.
48. P. Vollenweider, Insulin resistant states and insulin signaling, Clin Chem Lab Med 41 (2003), 1107-1119.
49. M. Schubert, D. Gautam, D. Surjo, K. Ueki, S. Baudler, D. Schubert, T. Kondo, J. Alber, N. Galldiks, E. Kustermann, S. Arndt, A.H. Jacobs, W. Krone, C.R. Kahn and J.C. Bruning, Role for neuronal insulin resistance in neurodegenerative diseases, Proc Natl Acad Sci USA 101 (2004), 3100-3105.
50. G. Pete, C.R. Fuller, J.M. Oldham, D.R. Smith, A.J. D'Ercole, C.R. Kahn and P.K. Lund, Postnatal growth responses to insulin-like growth factor I in insulin receptor substrate-1-deficient mice, Endocrinology 140 (1999), 5478-5487.
51. P. Ye, L. Li, P.K. Lund and A.J. D'Ercole, Deficient expression of insulin receptor substrate-1 (IRS-1) fails to block insulin-like growth factor-I (IGF-I) stimulation of brain growth and myelination, Brain Res Dev Brain Res 136 (2002), 111-121.
52. A. Virkamaki, K. Ueki and C.R. Kahn, Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance, J Clin Invest 103 (1999), 931-943.
53. M. Schubert, D.P. Brazil, D.J. Burks, J.A. Kushner, J. Ye, C.L. Flint, J. Farhang-Fallah, P. Dikkes, X.M. Warot, C. Rio, G. Corfas and M.F. White, Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation, J Neurosci 23 (2003), 7084-7092.
54. G. Bucht, R. Adolfsson, F. Lithner and B. Winblad, Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type, Acta Med Scand 213 (1983), 387-392.
55. M. Fisman, B. Gordon, V. Feleki, E. Helmes, T. McDonald and J. Dupre, Metabolic changes in Alzheimer's disease, J Am Geriatr Soc 36 (1988), 298-300.
56. S. Craft, S. Asthana, J.W. Newcomer, C.W. Wilkinson, I.T. Matos, L.D. Baker, M. Cherrier, C. Lofgreen, S. Latendresse, A. Petrova, S. Plymate, M. Raskind, K. Grimwood and R.C. Veith, Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose, Arch Gen Psychiatry 56 (1999), 1135-1140.
57. S. Craft, S. Asthana, D.G. Cook, L.D. Baker, M. Cherrier, K. Purganan, C. Wait, A. Petrova, S. Latendresse, G.S. Watson, J.W. Newcomer, G.D. Schellenberg and A.J. Krohn, Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype, Psychoneuroendocrinology 28 (2003), 809-822.
58. A. Ott, R.P. Stolk, A. Hofman, F. van Harskamp, D.E. Grobbee and M.M. Breteler, Association of diabetes mellitus and dementia: the Rotterdam Study, Diabetologia 39 (1996), 1392-1397.
59. A. Ott, R.P. Stolk, F. van Harskamp, H.A. Pols, A. Hofman and M.M. Breteler, Diabetes mellitus and the risk of dementia: The Rotterdam Study, Neurology 53 (1999), 1937-1942.
60. J. Heitner and D. Dickson, Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study, Neurology 49 (1997), 1306-1311.
61. T. den Heijer, S.E. Vermeer, E.J. van Dijk, N.D. Prins, P.J. Koudstaal, A. Hofman and M.M. Breteler, Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI, Diabetologia 46 (2003), 1604-1610.
62. J. Kuusisto, K. Koivisto, L. Mykkanen, E.L. Helkala, M. Vanhanen, T. Hanninen, K. Kervinen, Y.A. Kesaniemi, P.J. Riekkinen and M. Laakso, Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study, Bmj 315 (1997), 1045-1049.
63. S. Craft, S. Asthana, G. Schellenberg, M. Cherrier, L.D. Baker, J. Newcomer, S. Plymate, S. Latendresse, A. Petrova, M. Raskind, E. Peskind, C. Lofgreen and K. Grimwood, Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender, Neuroendocrinology 70 (1999), 146-152.
64. S. Craft, S. Asthana, G. Schellenberg, L. Baker, M. Cherrier, A.A. Boyt, R.N. Martins, M. Raskind, E. Peskind and S. Plymate, Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype, Ann N Y Acad Sci 903 (2000), 222-228.
65. C. Messier, Diabetes, Alzheimer's disease and apolipoprotein genotype, Exp Gerontol 38 (2003), 941-946.
66. J.C. de la Torre, Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis, Neurobiol Aging 21 (2000), 331-342.
67. D. Etiene, J. Kraft, N. Ganju, T. Gomez-Isla, B. Gemelli, B.T. Hyman, E.T. Hedley-Whyte, J.R. Wands and S.M. De La Monte, Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease, J Alzheimers Dis 1 (1998), 119-134.
68. S. Hoyer, Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update, Exp Gerontol 35 (2000), 1363-1372.
69. J.P. Blass, G.E. Gibson and S. Hoyer, The role of the metabolic lesion in Alzheimer's disease, J Alzheimers Dis 4 (2002), 225-232.
70. S. Hoyer, Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications, Adv Exp Med Biol 541 (2004), 135-152.
71. S. Hoyer, Glucose metabolism and insulin receptor signal transduction in Alzheimer disease, Eur J Pharmacol 490 (2004), 115-125.
72. D. Blum-Degen, L. Frolich, S. Hoyer and P. Riederer, Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm Suppl 46 (1995), 139-147.
73. G.A. Dienel and L. Hertz, Glucose and lactate metabolism during brain activation, J Neurosci Res 66 (2001), 824-838.
74. A.M. Brown, S. Baltan Tekkok and B.R. Ransom, Energy transfer from astrocytes to axons: the role of CNS glycogen, Neurochem Int 45 (2004), 529-536.
75. C.P. Chih and E.L. Roberts, Jr., Energy substrates for neurons during neural activity: a critical review of the astrocyteneuron lactate shuttle hypothesis, J Cereb Blood Flow Metab 23 (2003), 1263-1281.
76. G.S. Meneilly and A. Hill, Alterations in glucose metabolism in patients with Alzheimer's disease, J Am Geriatr Soc 41 (1993), 710-714.
77. M. Carantoni, G. Zuliani, M.R. Munari, K. D'Elia, E. Palmieri and R. Fellin, Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels, Dement Geriatr Cogn Disord 11 (2000), 176-180.
78. C. Messier and M. Gagnon, Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes, Behav Brain Res 75 (1996), 1-11.
79. S. Craft, S.E. Dagogo-Jack, B.V. Wiethop, C. Murphy, R.T. Nevins, S. Fleischman, V. Rice, J.W. Newcomer and P.E. Cryer, Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study, Behav Neurosci 107 (1993), 926-940.
80. S. Craft, J. Newcomer, S. Kanne, S. Dagogo-Jack, P. Cryer, Y. Sheline, J. Luby, A. Dagogo-Jack and A. Alderson, Memory improvement following induced hyperinsulinemia in Alzheimer's disease, Neurobiol Aging 17 (1996), 123-130.
81. S. Hoyer, R. Nitsch and K. Oesterreich, Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases, J Neural Transm Park Dis Dement Sect 3 (1991), 1-14.
82. S. Hoyer and R. Nitsch, Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type, J Neural Transm 75 (1989), 227-232.
83. Y. Fujisawa, K. Sasaki and K. Akiyama, Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type, Biol Psychiatry 30 (1991), 1219-1228.
84. J.A. Molina, F.J. Jimenez-Jimenez, C. Vargas, P. Gomez, F. de Bustos, C. Gomez-Escalonilla, M. Zurdo, A. Tallon, A. Martinez-Salio, J. Porta-Etessam, C. Villanueva and J. Arenas, Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease, Acta Neurol Scan J 106 (2002), 347-350.
85. L. Kilander, M. Boberg and H. Lithell, Peripheral glucose metabolism and insulin sensitivity in Alzheimer's disease, Acta Neurol Scand 87 (1993), 294-298.
86. S. Craft, E. Peskind, M.W. Schwartz, G.D. Schellenberg, M. Raskind and D. Porte, Jr., Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype, Neurology 50 (1998), 164-168.
87. G. Razay and G.K. Wilcock, Hyperinsulinaemia and Alzheimer's disease, Age Ageing 23 (1994), 396-399.
88. A.A. Spindler, M.J. Renvall, J.F. Nichols and J.W. Ramsdell, Nutritional status of patients with Alzheimer's disease: a 1-year study, J Am Diet Assoc 96 (1996), 1013-1018.
89. J.C. Reubi and J. Palacios, Somatostatin and Alzheimer's disease: a hypothesis, J Neurol 233 (1986), 370-372.
90. B. Connor, E.J. Beilharz, C. Williams, B. Synek, P.D. Gluckman, R.L. Faull and M. Dragunow, Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus, Brain Res Mol Brain Res 49 (1997), 283-290.
91. A. Tham, K. Sparring, D. Bowen, L. Wetterberg and V.R. Sara, Insulin-like growth factors and somatomedin B in the cerebrospinal fluid of patients with dementia of the Alzheimer type, Acta Psychiatr Scand 77 (1988), 719-723.
92. A. Tham, A. Nordberg, F.E. Grissom, C. Carlsson-Skwirut, M. Viitanen and V.R. Sara, Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type, J Neural Transm Park Dis Dement Sect 5 (1993), 165-176.
93. A. Mustafa, L. Lannfelt, L. Lilius, A. Islam, B. Winblad and A. Adem, Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation, Dement Geriatr Cogn Disord 10 (1999), 446-451.
94. F.T. Crews, R. McElhaney, G. Freund, W.E. Ballinger, D.W. Walker, B.E. Hunter and M.K. Raizada, Binding of [125I]-insulin-like growth factor-1 (IGF-I) in brains of Alzheimer's and alcoholic patients, Adv Exp Med Biol 293 (1991), 483-492.
95. F.T. Crews, R. McElhaney, G. Freund, W.E. Ballinger, Jr. and M.K. Raizada, Insulin-like growth factor I receptor binding in brains of Alzheimer's and alcoholic patients, J Neurochem 58 (1992), 1205-1210.
96. S. Jafferali, Y. Dumont, F. Sotty, Y. Robitaille, R. Quirion and S. Kar, Insulin-like growth factor-I and its receptor in the frontal cortex, hippocampus, and cerebellum of normal human and alzheimer disease brains, Synapse 38 (2000), 450-459.
97. J. De Keyser, N. Wilczak and A. Goossens, Insulin-like growth factor-I receptor densities in human frontal cortex and white matter during aging, in Alzheimer's disease, and in Huntington's disease, Neurosci Lett 172 (1994), 93-96.
98. I. Moroo, T. Yamada, H. Makino, I. Tooyama, P.L. McGeer, E.G. McGeer and K. Hirayama, Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease, Acta Neuropathol (Berl) 87 (1994), 343-348.
99. L. Frolich, D. Blum-Degen, P. Riederer and S. Hoyer, A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease, Ann N Y Acad Sci 893 (1999), 290-293.
100. L. Xie, E. Helmerhorst, K. Taddei, B. Plewright, W. Van Bronswijk and R. Martins, Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor, J Neurosci 22 (2002), RC221.
101. M.L. Fernandes, M.J. Saad and L.A. Velloso, Effects of age on elements of insulin-signaling pathway in central nervous system of rats, Endocrine 16 (2001), 227-234.
102. S. Hoyer, Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis, J Neural Transm 105 (1998), 415-422.
103. M. Hong and V.M. Lee, Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons, J Biol Chem 272 (1997), 19547-19553.
104. S. Lovestone, C.H. Reynolds, D. Latimer, D.R. Davis, B.H. Anderton, J.M. Gallo, D. Hanger, S. Mulot, B. Marquardt, S. Stabel et al., Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells, Curr Biol 4 (1994), 1077-1086.
105. J.J. Pei, I. Grundke-Iqbal, K. Iqbal, N. Bogdanovic, B. Winblad and R.F. Cowburn, Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration, Brain Res 797 (1998), 267-277.
106. T.D. Garver, G.A. Oyler, K.A. Harris, R. Polavarapu, Z. Damuni, R.A. Lehman and M.L. Billingsley, Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase, Mol Pharmacol 47 (1995), 745-756.
107. B.W. Doble and J.R. Woodgett, GSK-3: tricks of the trade for a multi-tasking kinase, J Cell Sci 116 (2003), 1175-1186.
108. M. Nishimura, G. Yu, G. Levesque, D.M. Zhang, L. Ruel, F. Chen, P. Milman, E. Holmes, Y. Liang, T. Kawarai, E. Jo, A. Supala, E. Rogaeva, D.M. Xu, C. Janus, L. Levesque, Q. Bi, M. Duthie, R. Rozmahel, K. Mattila, L. Lannfelt, D. Westaway, H.T. Mount, J. Woodgett and P. St George-Hyslop, Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex, Nat Med 5 (1999), 164-169.
109. G.V. De Ferrari and N.C. Inestrosa, Wnt signaling function in Alzheimer's disease, Brain Res Brain Res Rev 33 (2000), 1-12
110. A. Mudher, S. Chapman, J. Richardson, A. Asuni, G. Gibb, C. Pollard, R. Killick, T. Iqbal, L. Raymond, I. Varndell, P. Sheppard, A. Makoff, E. Gower, P.E. Soden, P. Lewis, M. Murphy, T.E. Golde, H.T. Rupniak, B.H. Anderton and S. Lovestone, Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase, J Neurosci 21 (2001), 4987-4995.
111. P.E. Fraser, G. Yu, L. Levesque, M. Nishimura, D.S. Yang, H.T. Mount, D. Westaway and P.H. St George-Hyslop, Presenilin function: connections to Alzheimer's disease and signal transduction, Biochem Soc Symp (2001), 89-100.
112. M. Grilli, G.F. Toninelli, D. Uberti, P. Spano and M. Memo, Alzheimer's disease linking neurodegeneration with neurodevelopment, Fund Neurol 18 (2003), 145-148.
113. G.J. Chen, J. Xu, S.A. Lahousse, N.L. Caggiano and S.M. de la Monte, Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection, J Alzheimers Dis 5 (2003), 209-228.
114. J.T. Egana, C. Zambrano, M.T. Nunez, C. Gonzalez-Billault and R.B. Maccioni, Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures, Biometals 16 (2003), 215-223.
115. E.M. Mandelkow, K. Stamer, R. Vogel, E. Thies and E. Mandelkow, Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses, Neurobiol Aging 24 (2003), 1079-1085.
116. X. Zhu, H.G. Lee, A.K. Raina, G. Perry and M.A. Smith, The role of mitogen-activated protein kinase pathways in Alzheimer's disease, Neurosignals 11 (2002), 270-281.
117. J.J. Pei, S. Khatoon, W.L. An, M. Nordlinder, T. Tanaka, H. Braak, I. Tsujio, M. Takeda, I. Alafuzoff, B. Winblad, R.F. Cowburn, I. Grundke-Iqbal and K. Iqbal, Role of protein kinase B in Alzheimer's neurofibrillary pathology, Acta Neuropathol (Berl) 105 (2003), 381-392.
118. A. Rickle, N. Bogdanovic, I. Volkman, B. Winblad, R. Ravid and R.F. Cowburn, Akt activity in Alzheimer's disease and other neurodegenerative disorders, Neuroreport 15 (2004), 955-959.
119. G.N. Patrick, L. Zukerberg, M. Nikolic, S. de la Monte, P. Dikkes and L.H. Tsai, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature 402 (1999), 615-622.
120. 2-induced Erk and Src kinase activity in human neuroblastoma cells, Neuroreport 13 (2002), 1057-1061.
121. A.J. Crossthwaite, S. Hasan and R.J. Williams, Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: dependence on Ca(2+) and PI3-kinase, J Neurochem 80 (2002), 24-35.
122. F. Kuperstein and E. Yavin, ERK activation and nuclear translocation in amyloid-beta peptide- and iron-stressed neuronal cell cultures, Eur J Neurosci 16 (2002), 44-54.
123. F. Kuperstein and E. Yavin, Pro-apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity, J Neurochem 86 (2003), 114-125.
124. 2-induced acute apoptosis in cultured neural stem/progenitor cells, FEBS Lett 570 (2004), 102-106.
125. L. Gasparini, G.K. Gouras, R. Wang, R.S. Gross, M.F. Beal, P. Greengard and H. Xu, Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling, J Neurosci 21 (2001), 2561-2570.
126. L. Gasparini, W.J. Netzer, P. Greengard and H. Xu, Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 23 (2002), 288-293.
127. X. Ling, R.N. Martins, M. Racchi, S. Craft and E. Helmerhorst, Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor, J Alzheimers Dis 4 (2002), 369-374.
128. G. Evin and A. Weidemann, Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides, Peptides 23 (2002), 1285-1297.
129. S. Dore, S. Kar and R. Quirion, Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity, Proc Natl Acad Sci USA 94 (1997), 4772-4777.
130. S. Dore, S. Bastianetto, S. Kar and R. Quirion, Protective and rescuing abilities of IGF-I and some putative free radical scavengers against beta-amyloid-inducing toxicity in neurons, Ann N Y Acad Sci 890 (1999), 356-364.
131. W.H. Zheng, S. Kar, S. Dore and R. Quirion, Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway, J Neural Transm Suppl (2000), 261-272.
132. S.M. de la Monte, T.R. Neely, J. Cannon and J.R. Wands, Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons, Cell Mol Life Sci 58 (2001), 1950-1960.
133. S.M. de laMonte and J.R. Wands, Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons, CMLS, Cell Mol Life Sci 59 (2002), 882-893.
134. S.M. de la Monte, N. Ganju, K. Banerjee, N.V. Brown, T. Luong and J.R. Wands, Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase, Alcohol Clin Exp Res 24 (2000), 716-726.
135. G.G. Glenner and C.W Wong, Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun 120 (1984), 885-890.
136. E. Tsukamoto, Y. Hashimoto, K. Kanekura, T. Niikura, S. Aiso and I. Nishimoto, Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells, J Neurosci Res 73 (2003), 627-636.
137. J.R. McDermott and A.M. Gibson, Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme, Neurochem Res 22 (1997), 49-56.
138. W.Q. Qiu, D.M. Walsh, Z. Ye, K. Vekrellis, J. Zhang, M.B. Podlisny, M.R. Rosner, A. Safavi, L.B. Hersh and D.J. Selkoe, Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation, J Biol Chem 273 (1998), 32730-32738.
139. A. Perez, L. Morelli, J.C. Cresto and E.M. Castano, Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains, Neurochem Res 25 (2000), 247-255.
140. K. Vekrellis, Z. Ye, W.Q. Qiu, D. Walsh, D. Hartley, V. Chesneau, M.R. Rosner and D.J. Selkoe, Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme, J Neurosci 20 (2000), 1657-1665.
141. A.S. Balasubramanian, Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase, Neumchem Res 26 (2001), 453-456.
142. H.G. Bernstein, S. Ansorge, P. Riederer, M. Reiser, L. Frolich and B. Bogerts, Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques, Neurosci Lett 263 (1999), 161-164.
143. D.G. Cook, J.B. Leverenz, P.J. McMillan, J.J. Kulstad, S. Ericksen, R.A. Roth, G.D. Schellenberg, L.W. Jin, K.S. Kovacina and S. Craft, Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele, Am J Pathol 162 (2003), 313-319.
144. W. Farris, S. Mansourian, M.A. Leissring, E.A. Eckman, L. Bertram, C.B. Eckman, R.E. Tanzi and D.J. Selkoe, Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein, Am J Pathol 164 (2004), 1425-1434.
145. W. Farris, S. Mansourian, Y. Chang, L. Lindsley, E.A. Eckman, M.P. Frosch, C.B. Eckman, R.E. Tanzi, D.J. Selkoe and S. Guenette, Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo, Proc Natl Acad Sci USA 100 (2003), 4162-4167.
146. M.A. Leissring, W. Farris, A.Y. Chang, D.M. Walsh, X. Wu, X. Sun, M.P. Frosch and D.J. Selkoe, Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death, Neuron 40 (2003), 1087-1093.
147. L. Bertram, D. Blacker, K. Mullin, D. Keeney, J. Jones, S. Basu, S. Yhu, M.G. McInnis, R.C. Go, K. Vekrellis, D.J. Selkoe, A.J. Saunders and R.E. Tanzi, Evidence for genetic linkage of Alzheimer's disease to chromosome 1Oq, Science 290 (2000), 2302-2303.
148. R. Abraham, A. Myers, F. Wavrant-DeVrieze, M.L. Hamshere, H.V. Thomas, H. Marshall, D. Compton, G. Spurlock, D. Turic, B. Hoogendoorn, J.M. Kwon, R.C. Petersen, E. Tangalos, J. Norton, J.C. Morris, R. Bullock, D. Liolitsa, S. Lovestone, J. Hardy, A. Goate, M. O'Donovan, J. Williams, M.J. Owen and L. Jones, Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease, Hum Genet 109 (2001), 646-652.
149. G. Ait-Ghezala, L. Abdullah, R. Crescentini, F. Crawford, T. Town, S. Singh, D. Richards, R. Duara and M. Mullan, Confirmation of association between D10S583 and Alzheimer's disease in a case - control sample, Neurosci Lett 325 (2002), 87-90,
150. M. Boussaha, D. Hannequin, P. Verpillat, A. Brice, T. Frebourg and D. Campion, Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease, Neurosci Lett 329 (2002), 121-123.
151. S. Hoyer, Age as risk factor for sporadic dementia of the Alzheimer type? Ann N Y Acad Sci 719 (1994), 248-256.
152. S. Hoyer, D. Muller and K. Plaschke, Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism, J Neural Transm Suppl 44 (1994), 259-268.
153. S. Hoyer, Neurodegeneration, Alzheimer's disease, and beta-amyloid toxicity, Life Sci 55 (1994), 1977-1983.
154. S. Hoyer, Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease, Acta Neurol Scand Suppl 165 (1996), 18-24.
155. S. Hoyer, The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update, J Neural Transm 109 (2002), 341-360.
156. S. Hoyer, The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review, J Neural Transm 109 (2002), 991-1002.
157. K. Plaschke and S. Hoyer, Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus, Int J Dev Neurosci 11 (1993), 477-483.
158. R. Duelli, H. Schrock, W. Kuschinsky and S. Hoyer, Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci 12 (1994), 737-743.
159. S. Hoyer, S.K. Lee, T. Loffler and R. Schliebs, Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920 (2000), 256-258.
160. S. Hoyer and H. Lannert, Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats, Ann N Y Acad Sci 893 (1999), 301-303.
161. H. Lannert and S. Hoyer, Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats, Behav Neurosci 112 (1998), 1199-1208.
162. Y. Miyazaki, H. He, L.J. Mandarino and R.A. DeFronzo, Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients, Diabetes 52 (2003), 1943-1950.
163. E.H. Koh, M.S. Kim, J.Y. Park, H.S. Kim, J.Y. Youn, H.S. Park, J.H. Youn and K.U. Lee, Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation, Diabetes 52 (2003), 2331-2337.
164. S.M. de la Monte and J.R. Wands, Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling, J Alzheimers Dis 6 (2004), 231-242.
165. R.V. Bhat, S.L. Budd Haeberlein and J. Avila, Glycogen synthase kinase 3: a drug target for CNS therapies, J Neurochem 89 (2004), 1313-1317.